S-1联合吉非替尼治疗晚期NSCLC EGFR-TKI获得性耐药的临床疗效

Jing-yan Shen, B. Han, Shuying Wang, Hai-Li Kang, Lidong Wang, Xu-hui Liu, Qinggui Cui
{"title":"S-1联合吉非替尼治疗晚期NSCLC EGFR-TKI获得性耐药的临床疗效","authors":"Jing-yan Shen, B. Han, Shuying Wang, Hai-Li Kang, Lidong Wang, Xu-hui Liu, Qinggui Cui","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.12.004","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the clinical effect of S-1 combined with gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) with acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). \n \n \nMethods \nA total of 74 patients with advanced NSCLC were selected as the study subjects from January 2016 to August 2017 in Qian′an People′s Hospital of Hebei Province. The patients were divided into control group (n=37) and experimental group (n=37) by random number table method. The control group was given sequential gefitinib with pemetrexed, and the experimental group was given S-1 combined with gefitinib. The clinical efficacy and adverse reactions of the two groups were compared. \n \n \nResults \nThe effective rates of the control group and the experimental group were 21.62% (8/37) and 27.03% (10/37) respectively, and the difference was not statistically significant (χ2=0.294, P=0.588). The disease control rates were 75.68% (28/37) and 78.38% (29/37) respectively, and the difference was not statistically significant (χ2=0.076, P=0.782). The median progression-free survival of the control group and the experimental group were 8.4 months and 8.2 months, and the median overall survival were 9.8 months and 10.5 months respectively, and the differences were not statistically significant (χ2=0.186, P=0.666; χ2=0.608, P=0.436). The occurrence rate of diarrhea was 56.76% (21/37) in the control group and 62.16% (23/37) in the experimental group, with no significant difference (χ2=0.224, P=0.636). The occurrence rates of rash in the control group and the experimental group were 62.16% (23/37) and 13.51% (5/37), the occurrence rates of leukopenia were 35.14% (13/37) and 5.41% (2/37), the occurrence rates of thrombocytopenia were 27.03% (10/37) and 2.70% (1/37), the occurrence rates of anemia were 40.54% (15/37) and 10.81% (4/37), and the occurrence rates of liver damage were 18.92% (7/37) and 0 (0/37). The occurrence rates of the above adverse reactions in the experimental group were significantly lower than those in the control group, and the differences were statistically significant (χ2=18.615, P<0.001; χ2=10.118, P=0.001; χ2=8.650, P=0.003; χ2=8.568, P=0.003; χ2=5.680, P=0.017). There were no grade Ⅲ-Ⅳ adverse reactions in the two groups. \n \n \nConclusion \nThe combination of S-1 and gefitinib is effective in the treatment of advanced NSCLC with acquired resistance to EGFR-TKI and well tolerated, with mild adverse reactions, and oral administration is easy for patients to accept. It is an ideal way for clinical treatment of advanced NSCLC with EGFR-TKI acquired resistance. \n \n \nKey words: \nCarcinoma, non-small-cell lung; Pemetrexed; Epidermal growth factor receptor-tyrosine kinase inhibitor; Acquired drug resistance; S-1","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"3 1","pages":"723-727"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical efficacy of S-1 combined with gefitinib in the treatment of advanced NSCLC with EGFR-TKI acquired drug resistance\",\"authors\":\"Jing-yan Shen, B. Han, Shuying Wang, Hai-Li Kang, Lidong Wang, Xu-hui Liu, Qinggui Cui\",\"doi\":\"10.3760/CMA.J.ISSN.1673-422X.2019.12.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo explore the clinical effect of S-1 combined with gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) with acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). \\n \\n \\nMethods \\nA total of 74 patients with advanced NSCLC were selected as the study subjects from January 2016 to August 2017 in Qian′an People′s Hospital of Hebei Province. The patients were divided into control group (n=37) and experimental group (n=37) by random number table method. The control group was given sequential gefitinib with pemetrexed, and the experimental group was given S-1 combined with gefitinib. The clinical efficacy and adverse reactions of the two groups were compared. \\n \\n \\nResults \\nThe effective rates of the control group and the experimental group were 21.62% (8/37) and 27.03% (10/37) respectively, and the difference was not statistically significant (χ2=0.294, P=0.588). The disease control rates were 75.68% (28/37) and 78.38% (29/37) respectively, and the difference was not statistically significant (χ2=0.076, P=0.782). The median progression-free survival of the control group and the experimental group were 8.4 months and 8.2 months, and the median overall survival were 9.8 months and 10.5 months respectively, and the differences were not statistically significant (χ2=0.186, P=0.666; χ2=0.608, P=0.436). The occurrence rate of diarrhea was 56.76% (21/37) in the control group and 62.16% (23/37) in the experimental group, with no significant difference (χ2=0.224, P=0.636). The occurrence rates of rash in the control group and the experimental group were 62.16% (23/37) and 13.51% (5/37), the occurrence rates of leukopenia were 35.14% (13/37) and 5.41% (2/37), the occurrence rates of thrombocytopenia were 27.03% (10/37) and 2.70% (1/37), the occurrence rates of anemia were 40.54% (15/37) and 10.81% (4/37), and the occurrence rates of liver damage were 18.92% (7/37) and 0 (0/37). The occurrence rates of the above adverse reactions in the experimental group were significantly lower than those in the control group, and the differences were statistically significant (χ2=18.615, P<0.001; χ2=10.118, P=0.001; χ2=8.650, P=0.003; χ2=8.568, P=0.003; χ2=5.680, P=0.017). There were no grade Ⅲ-Ⅳ adverse reactions in the two groups. \\n \\n \\nConclusion \\nThe combination of S-1 and gefitinib is effective in the treatment of advanced NSCLC with acquired resistance to EGFR-TKI and well tolerated, with mild adverse reactions, and oral administration is easy for patients to accept. It is an ideal way for clinical treatment of advanced NSCLC with EGFR-TKI acquired resistance. \\n \\n \\nKey words: \\nCarcinoma, non-small-cell lung; Pemetrexed; Epidermal growth factor receptor-tyrosine kinase inhibitor; Acquired drug resistance; S-1\",\"PeriodicalId\":16120,\"journal\":{\"name\":\"国际肿瘤学杂志\",\"volume\":\"3 1\",\"pages\":\"723-727\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-12-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际肿瘤学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.12.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的探讨S-1联合吉非替尼治疗表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI)获得性耐药晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取2016年1月~ 2017年8月河北省迁安市人民医院晚期非小细胞肺癌患者74例作为研究对象。采用随机数字表法将患者分为对照组(n=37)和实验组(n=37)。对照组患者给予吉非替尼联合培美曲塞序贯治疗,实验组患者给予S-1联合吉非替尼治疗。比较两组患者的临床疗效及不良反应。结果对照组和实验组有效率分别为21.62%(8/37)和27.03%(10/37),差异无统计学意义(χ2=0.294, P=0.588)。疾病控制率分别为75.68%(28/37)、78.38%(29/37),差异无统计学意义(χ2=0.076, P=0.782)。对照组和实验组的中位无进展生存期分别为8.4个月和8.2个月,中位总生存期分别为9.8个月和10.5个月,差异无统计学意义(χ2=0.186, P=0.666;χ2 = 0.608,P = 0.436)。对照组腹泻发生率为56.76%(21/37),试验组为62.16%(23/37),差异无统计学意义(χ2=0.224, P=0.636)。对照组和实验组皮疹发生率分别为62.16%(23/37)和13.51%(5/37),白细胞减少发生率分别为35.14%(13/37)和5.41%(2/37),血小板减少发生率分别为27.03%(10/37)和2.70%(1/37),贫血发生率分别为40.54%(15/37)和10.81%(4/37),肝损害发生率分别为18.92%(7/37)和0(0/37)。实验组上述不良反应发生率均显著低于对照组,差异均有统计学意义(χ2=18.615, P<0.001;χ2 = 10.118,P = 0.001;χ2 = 8.650,P = 0.003;χ2 = 8.568,P = 0.003;χ2 = 5.680,P = 0.017)。两组患者均无Ⅲ-Ⅳ级不良反应。结论S-1联合吉非替尼治疗EGFR-TKI获得性耐药的晚期NSCLC疗效显著,且耐受性好,不良反应轻,口服给药易于患者接受。是EGFR-TKI获得性耐药晚期NSCLC临床治疗的理想途径。关键词:肺癌,非小细胞肺;培美曲塞;表皮生长因子受体酪氨酸激酶抑制剂;获得性耐药;s - 1
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical efficacy of S-1 combined with gefitinib in the treatment of advanced NSCLC with EGFR-TKI acquired drug resistance
Objective To explore the clinical effect of S-1 combined with gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) with acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). Methods A total of 74 patients with advanced NSCLC were selected as the study subjects from January 2016 to August 2017 in Qian′an People′s Hospital of Hebei Province. The patients were divided into control group (n=37) and experimental group (n=37) by random number table method. The control group was given sequential gefitinib with pemetrexed, and the experimental group was given S-1 combined with gefitinib. The clinical efficacy and adverse reactions of the two groups were compared. Results The effective rates of the control group and the experimental group were 21.62% (8/37) and 27.03% (10/37) respectively, and the difference was not statistically significant (χ2=0.294, P=0.588). The disease control rates were 75.68% (28/37) and 78.38% (29/37) respectively, and the difference was not statistically significant (χ2=0.076, P=0.782). The median progression-free survival of the control group and the experimental group were 8.4 months and 8.2 months, and the median overall survival were 9.8 months and 10.5 months respectively, and the differences were not statistically significant (χ2=0.186, P=0.666; χ2=0.608, P=0.436). The occurrence rate of diarrhea was 56.76% (21/37) in the control group and 62.16% (23/37) in the experimental group, with no significant difference (χ2=0.224, P=0.636). The occurrence rates of rash in the control group and the experimental group were 62.16% (23/37) and 13.51% (5/37), the occurrence rates of leukopenia were 35.14% (13/37) and 5.41% (2/37), the occurrence rates of thrombocytopenia were 27.03% (10/37) and 2.70% (1/37), the occurrence rates of anemia were 40.54% (15/37) and 10.81% (4/37), and the occurrence rates of liver damage were 18.92% (7/37) and 0 (0/37). The occurrence rates of the above adverse reactions in the experimental group were significantly lower than those in the control group, and the differences were statistically significant (χ2=18.615, P<0.001; χ2=10.118, P=0.001; χ2=8.650, P=0.003; χ2=8.568, P=0.003; χ2=5.680, P=0.017). There were no grade Ⅲ-Ⅳ adverse reactions in the two groups. Conclusion The combination of S-1 and gefitinib is effective in the treatment of advanced NSCLC with acquired resistance to EGFR-TKI and well tolerated, with mild adverse reactions, and oral administration is easy for patients to accept. It is an ideal way for clinical treatment of advanced NSCLC with EGFR-TKI acquired resistance. Key words: Carcinoma, non-small-cell lung; Pemetrexed; Epidermal growth factor receptor-tyrosine kinase inhibitor; Acquired drug resistance; S-1
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
12123
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信